JP2022553569A - うつ病性障害の治療方法 - Google Patents

うつ病性障害の治療方法 Download PDF

Info

Publication number
JP2022553569A
JP2022553569A JP2022524695A JP2022524695A JP2022553569A JP 2022553569 A JP2022553569 A JP 2022553569A JP 2022524695 A JP2022524695 A JP 2022524695A JP 2022524695 A JP2022524695 A JP 2022524695A JP 2022553569 A JP2022553569 A JP 2022553569A
Authority
JP
Japan
Prior art keywords
compound
human
administered
dose
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022524695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553569A5 (enExample
Inventor
シンシア ルイーズ ハーデン
グレゴリー エヌ． ビーッチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of JP2022553569A publication Critical patent/JP2022553569A/ja
Publication of JP2022553569A5 publication Critical patent/JP2022553569A5/ja
Priority to JP2025155966A priority Critical patent/JP2026001049A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022524695A 2019-11-08 2020-11-06 うつ病性障害の治療方法 Pending JP2022553569A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025155966A JP2026001049A (ja) 2019-11-08 2025-09-19 うつ病性障害の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932724P 2019-11-08 2019-11-08
US62/932,724 2019-11-08
PCT/US2020/059481 WO2021092439A1 (en) 2019-11-08 2020-11-06 Methods of treating depressive disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025155966A Division JP2026001049A (ja) 2019-11-08 2025-09-19 うつ病性障害の治療方法

Publications (2)

Publication Number Publication Date
JP2022553569A true JP2022553569A (ja) 2022-12-23
JP2022553569A5 JP2022553569A5 (enExample) 2023-11-14

Family

ID=73643360

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022524695A Pending JP2022553569A (ja) 2019-11-08 2020-11-06 うつ病性障害の治療方法
JP2025155966A Pending JP2026001049A (ja) 2019-11-08 2025-09-19 うつ病性障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025155966A Pending JP2026001049A (ja) 2019-11-08 2025-09-19 うつ病性障害の治療方法

Country Status (19)

Country Link
US (2) US12178811B2 (enExample)
EP (1) EP4054580A1 (enExample)
JP (2) JP2022553569A (enExample)
KR (1) KR20220098746A (enExample)
CN (1) CN114667146A (enExample)
AU (1) AU2020380961A1 (enExample)
BR (1) BR112022008580A2 (enExample)
CA (1) CA3155812A1 (enExample)
CL (1) CL2022001102A1 (enExample)
CO (1) CO2022008001A2 (enExample)
CR (1) CR20220250A (enExample)
GE (2) GEP20257732B (enExample)
IL (1) IL292678A (enExample)
MA (1) MA56607A1 (enExample)
MX (1) MX2022005490A (enExample)
PE (1) PE20221766A1 (enExample)
PH (1) PH12022551110A1 (enExample)
TW (1) TW202128162A (enExample)
WO (1) WO2021092439A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3155812A1 (en) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methods of treating depressive disorders
CA3159876A1 (en) 2019-12-06 2021-06-10 James MURROUGH Method of treatment with kcnq channel openers
GEAP202416349A (en) * 2021-02-09 2024-02-12 Xenon Pharmaceuticals Inc Conjoint therapy for treating seizure disorders
TW202245744A (zh) 2021-02-09 2022-12-01 加拿大商再諾製藥公司 治療失樂症之方法及用途
EP4392125A1 (en) * 2021-10-08 2024-07-03 Albert-Ludwigs-Universität Freiburg Treatment of psychiatric disorders with deep brain stimulation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501568A (ja) * 2006-08-23 2010-01-21 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
JP2011506391A (ja) * 2007-12-11 2011-03-03 ノイロサーチ アクティーゼルスカブ カリウムチャネル活性化因子として有用な、新規の２−エチル−メチル−アミノ−３−アミド−６−アミノ−ピリジン誘導体
JP2011513196A (ja) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
JP2013518815A (ja) * 2010-02-01 2013-05-23 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
JP2021519814A (ja) * 2018-02-20 2021-08-12 ハー・ルンドベック・アクチエゼルスカベット Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639385A (en) 1968-07-26 1972-02-01 Eastman Kodak Co Heterocyclic monoazo compounds from n n-diaralkyl anilines and polyester textile materials dyed therewith
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4181803A (en) 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
EP0110091B1 (de) 1982-10-27 1987-01-21 Degussa Aktiengesellschaft 2-Amino-3-Acylamino-6-benzylamino-pyridin-Derivate mit anti-epileptischer Wirkung
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
EP0193056B1 (de) 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
JP2583067B2 (ja) 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (enExample) 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5428039A (en) 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
JP4097285B2 (ja) 1994-09-22 2008-06-11 リチャード・アラン・スミス 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
RU2180852C2 (ru) 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US6218411B1 (en) 1997-08-08 2001-04-17 Chugai Seiyaku Kabushiki Kaisha Therapeutics for diabetic complications
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
US6395736B1 (en) 1998-12-14 2002-05-28 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
JP2003521468A (ja) 1999-03-17 2003-07-15 シグナル ファーマシューティカルズ， インコーポレイテッド エストロゲンレセプタを変調させるための化合物及び方法
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
DZ3209A1 (fr) 1999-07-06 2001-01-11 Lilly Co Eli Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
EP1208085B1 (en) 1999-08-04 2007-12-05 Icagen, Inc. Benzanilides as potassium channel openers
EP1200086A4 (en) 1999-08-04 2009-05-27 Icagen Inc THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
US20020183395A1 (en) 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003068769A1 (en) 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
AU2003241453A1 (en) 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
WO2003106454A1 (en) 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd 1h-isoquinoline-oxazolidinone derivaties and their use as antibacterial agents
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
AU2003294441A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
CA2505195C (en) 2002-12-23 2012-07-10 Icagen, Inc. Quinazolinones as potassium channel modulators
ES2282701T3 (es) 2002-12-27 2007-10-16 H. Lundbeck A/S Derivados de 1,2,4-triaminobenceno utiles para tratar trastornos del sistema nervioso central.
WO2004080950A1 (en) 2003-03-14 2004-09-23 H. Lundbeck A/S Substituted aniline derivatives
US7906537B2 (en) 2003-03-21 2011-03-15 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
MXPA05010174A (es) 2003-04-25 2005-11-08 Lundbeck & Co As H Derivados de indol e indolina sustituidos.
CA2526566A1 (en) 2003-05-27 2004-12-09 Altana Pharma Ag Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
EP1737852A2 (en) 2004-04-13 2007-01-03 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
MXPA06012685A (es) 2004-05-03 2007-01-16 Univ Duke Composiciones para afectar la perdida de peso.
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
EP1813285A4 (en) 2004-11-19 2010-06-09 Kissei Pharmaceutical PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST NEUROPATHIC PAIN
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
CA2599890C (en) 2005-03-03 2011-05-03 H. Lundbeck A/S Substituted pyridine derivatives
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
US7683058B2 (en) 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
EP2012769A1 (en) 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
KR20090083479A (ko) 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
WO2008144320A2 (en) 2007-05-17 2008-11-27 Endo Pharmaceuticals, Inc. Opioid and methods of making and using the same
US20100323016A1 (en) 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
CA2787247A1 (en) 2010-01-20 2011-07-28 Glaxo Group Limited Novel composition
WO2013067591A1 (en) 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
MA52569B1 (fr) 2018-05-11 2023-11-30 Xenon Pharmaceuticals Inc Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (en) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methods of treating depressive disorders
CA3159876A1 (en) 2019-12-06 2021-06-10 James MURROUGH Method of treatment with kcnq channel openers
US20210213009A1 (en) 2019-12-13 2021-07-15 Xenon Pharmaceuticals Inc. Methods of treating pain
GEAP202416349A (en) 2021-02-09 2024-02-12 Xenon Pharmaceuticals Inc Conjoint therapy for treating seizure disorders
TW202245744A (zh) 2021-02-09 2022-12-01 加拿大商再諾製藥公司 治療失樂症之方法及用途
CN113698345B (zh) 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501568A (ja) * 2006-08-23 2010-01-21 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
JP2011513196A (ja) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
JP2011506391A (ja) * 2007-12-11 2011-03-03 ノイロサーチ アクティーゼルスカブ カリウムチャネル活性化因子として有用な、新規の２−エチル−メチル−アミノ−３−アミド−６−アミノ−ピリジン誘導体
JP2013518815A (ja) * 2010-02-01 2013-05-23 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
JP2021519814A (ja) * 2018-02-20 2021-08-12 ハー・ルンドベック・アクチエゼルスカベット Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol. 58, JPN7024004572, 6 October 2017 (2017-10-06), pages 625 - 648, ISSN: 0005447690 *
EPILEPSIA, vol. 59, JPN7024004575, 9 October 2018 (2018-10-09), pages 1811 - 1841, ISSN: 0005447692 *
MOL. PSYCHIATRY, vol. 25(6), JPN7024004574, 2 May 2019 (2019-05-02), pages 1323 - 1333, ISSN: 0005447691 *
NATURE COMMUNICATIONS, vol. 7, no. 11671, JPN6024043563, 2016, pages 1 - 7, ISSN: 0005596998 *

Also Published As

Publication number Publication date
TW202128162A (zh) 2021-08-01
MA56607A1 (fr) 2022-10-31
NZ787838A (en) 2025-08-29
GEAP202415942A (en) 2024-10-28
KR20220098746A (ko) 2022-07-12
IL292678A (en) 2022-07-01
PH12022551110A1 (en) 2024-02-26
MX2022005490A (es) 2022-08-10
CR20220250A (es) 2022-08-19
CL2022001102A1 (es) 2023-01-27
CA3155812A1 (en) 2021-05-14
CN114667146A (zh) 2022-06-24
GEP20257732B (en) 2025-02-10
CO2022008001A2 (es) 2022-06-10
AU2020380961A1 (en) 2022-05-26
EP4054580A1 (en) 2022-09-14
US20210161886A1 (en) 2021-06-03
US20250108044A1 (en) 2025-04-03
US12178811B2 (en) 2024-12-31
JP2026001049A (ja) 2026-01-06
BR112022008580A2 (pt) 2022-08-09
PE20221766A1 (es) 2022-11-11
WO2021092439A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
US12178811B2 (en) Methods of treating depressive disorders
US12521426B2 (en) Methods and compositions for inhibiting glyoxalase 1 (GLO1)
Hanif et al. Neuroprotective effects of voluntary exercise in an inherited retinal degeneration mouse model
De Oliveira et al. The effect of venlafaxine on behaviour, body weight and striatal monoamine levels on sleep-deprived female rats
Doze et al. Long-term α1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity
Rodriguiz et al. Assessments of cognitive deficits in mutant mice
EP2291181B1 (en) Captodiamine for the treatment of depression symptoms
Blazevic et al. Anxiety-like behavior and cognitive flexibility in adult rats perinatally exposed to increased serotonin concentrations
JP2009114084A (ja) 水素分子を含む神経新生を促進する組成物
Al-Jarrah et al. Endurance exercise training protects against the upregulation of nitric oxide in the striatum of MPTP/probenecid mouse model of Parkinson's disease
Maloney et al. Examining the reversibility of long-term behavioral disruptions in progeny of maternal SSRI exposure
JP2024508660A (ja) 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬
McAdam et al. Altered water–maze search behavior in adult guinea pigs following chronic prenatal ethanol exposure: Lack of mitigation by postnatal fluoxetine treatment
EA048968B1 (ru) Способы лечения депрессивных расстройств
CA3195241A1 (en) Compositions and uses thereof
JP2023550093A (ja) レット症候群を治療するためのプリドピジンまたはその類似体の使用
WO2021082826A1 (zh) 银杏内酯a治疗自闭症的用途
WO2023215338A1 (en) Compositions and methods for treating cluster headache
Saad D-β-Hydroxybutyrate and lactate mediate the positive effects of exercise on chronic stress by changing the histone modification profile in the hippocampus
HK40076951A (en) Methods of treating depressive disorders
KR20240121572A (ko) 페오놀을 유효성분으로 포함하는 정신장애의 예방 또는 치료용 약학적 조성물
Levina et al. P. 4.014 Comparative study of Ladasten, Sydnocarb and their combination effects
QUESSEVEUR et al. New strategies for the treatment of mood disorders: the triple reuptake inhibitors
Bhat Comparative study of the antidepressant activity of ethanol Extract of areca catechu and imipramine in mice
Milind Parle et al. A review on animal models of depression.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250430

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250805

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250812